ClinicalTrials.Veeva

Menu
P

Physician Research Collaboration, LLC | Lincoln, NE

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Methotrexate
Upadacitinib
Ixekizumab
Tofacitinib
Tanezumab
Tc 99m
CP-690,550
Abatacept
Risankizumab
Dupilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 57 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting
Joint Diseases
Arthritis
Drug: Peresolimab
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the...

Active, not recruiting
Knee Osteoarthritis
Biological: Amniotic Suspension Allograft
Drug: Placebo

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight receive ixekizumab and tir...

Enrolling
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Device: Non-active stimulation

Trial sponsors

Pfizer logo
AbbVie logo
Lilly logo
Bristol-Myers Squibb (BMS) logo
Sandoz logo
CSL Behring logo
N
Amgen logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems